Does atomoxetine improve executive function, inhibitory control, and hyperactivity?: results from a placebo-controlled trial using quantitative measurement technology
The primary objective of this study was to evaluate the efficacy of atomoxetine (ATX) on attention-deficit/hyperactivity disorder (ADHD)-related symptoms assessed as standard variables of a computer-based continuous performance test (cb-CPT) combined with a motion-tracking (MT) device. This was a 2-...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
Journal of clinical psychopharmacology
Year: 2012, Jahrgang: 32, Heft: 5, Pages: 653-660 |
| ISSN: | 1533-712X |
| DOI: | 10.1097/JCP.0b013e318267c304 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1097/JCP.0b013e318267c304 Verlag, Volltext: http://journals.lww.com/psychopharmacology/fulltext/2012/10000/Does_Atomoxetine_Improve_Executive_Function,.11.aspx 
|
| Verfasserangaben: | Peter M. Wehmeier, MD, Alexander Schacht, PhD, Fredrik Ulberstad, MSc, Martin Lehmann, PhD, Christian Schneider-Fresenius, PhD, Gerd Lehmkuhl, MD, Ralf W. Dittmann, MD, PhD, and Tobias Banaschewski, MD, PhD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580475698 | ||
| 003 | DE-627 | ||
| 005 | 20220814234209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180828s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/JCP.0b013e318267c304 |2 doi | |
| 035 | |a (DE-627)1580475698 | ||
| 035 | |a (DE-576)510475698 | ||
| 035 | |a (DE-599)BSZ510475698 | ||
| 035 | |a (OCoLC)1341017607 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wehmeier, Peter M. |d 1963- |e VerfasserIn |0 (DE-588)112354939 |0 (DE-627)503816221 |0 (DE-576)289728894 |4 aut | |
| 245 | 1 | 0 | |a Does atomoxetine improve executive function, inhibitory control, and hyperactivity? |b results from a placebo-controlled trial using quantitative measurement technology |c Peter M. Wehmeier, MD, Alexander Schacht, PhD, Fredrik Ulberstad, MSc, Martin Lehmann, PhD, Christian Schneider-Fresenius, PhD, Gerd Lehmkuhl, MD, Ralf W. Dittmann, MD, PhD, and Tobias Banaschewski, MD, PhD |
| 264 | 1 | |c 2012 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.08.2018 | ||
| 520 | |a The primary objective of this study was to evaluate the efficacy of atomoxetine (ATX) on attention-deficit/hyperactivity disorder (ADHD)-related symptoms assessed as standard variables of a computer-based continuous performance test (cb-CPT) combined with a motion-tracking (MT) device. This was a 2-arm, 8-week, randomized, double-blind, placebo-controlled study in patients with ADHD (6-12 years). Therapy with ATX started with 0.5 mg/kg per day for 1 week, followed by 7 weeks on the target dosage of 1.2 mg/kg per day. Primary outcomes were cb-CPT/MT standard scores after 8 weeks using mixed models for repeated measurements. In addition, investigator-rated ADHD Rating Scale (ADHD-RS), Weekly Ratings of Evening and Morning Behavior (WREMB), and Clinical Global Impression - Severity-ADHD (CGI-S-ADHD) scores were assessed. Of 128 patients randomized, 125 were evaluated (ATX/placebo: 63/62). Baseline characteristics were comparable in both groups (overall, 80.2% boys; mean [SD] age, 9.0 [1.79] years; comorbid Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis, 40.0% oppositional defiant disorder/conduct disorder; prior stimulant treatment, 24.8%; ADHD-RS total score, 36.99 [11.56]). At week 8, all cb-CPT/MT q-scores were significantly reduced versus placebo (all P < 0.001) with effect sizes (ESs) of reaction time (RT) variation (ES = 0.71), mean RT (ES = 0.41), number of microevents (ES = 1.00), commission error rate (ES = 0.50), distance of movement (ES = 0.90), area of movement (ES = 1.08), omission error rate (ES = 0.70), time active (ES = 0.69), motion simplicity (ES = 0.38), and normalized variance of RT (ES = 0.50). Secondary end points also improved significantly in favor of ATX: ADHD-RS (total score ES = 1.30, P < 0.001; hyperactivity/impulsivity subscore ES = 1.37, P < 0.001; inattention subscore ES = 1.07, P < 0.001), WREMB (total score ES = 1.00, P < 0.001; morning subscore ES = 0.59, P = 0.002; evening subscore ES = 1.02, P < 0.001), CGI-S-ADHD (ES = 1.11, P < 0.001). The results of this study show that ATX for 8 weeks significantly reduced ADHD-related symptoms as measured by the cb-CPT/MT. | ||
| 700 | 1 | |a Dittmann, Ralf |e VerfasserIn |0 (DE-588)1032941170 |0 (DE-627)739784323 |0 (DE-576)38041337X |4 aut | |
| 700 | 1 | |a Banaschewski, Tobias |d 1961- |e VerfasserIn |0 (DE-588)115856110 |0 (DE-627)507227301 |0 (DE-576)178364703 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical psychopharmacology |d Hagerstown, Md. : Lippincott Williams & Wilkins, 1981 |g 32(2012), 5, Seite 653-660 |h Online-Ressource |w (DE-627)33428998X |w (DE-600)2057059-4 |w (DE-576)098000314 |x 1533-712X |7 nnas |a Does atomoxetine improve executive function, inhibitory control, and hyperactivity? results from a placebo-controlled trial using quantitative measurement technology |
| 773 | 1 | 8 | |g volume:32 |g year:2012 |g number:5 |g pages:653-660 |g extent:8 |a Does atomoxetine improve executive function, inhibitory control, and hyperactivity? results from a placebo-controlled trial using quantitative measurement technology |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/JCP.0b013e318267c304 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://journals.lww.com/psychopharmacology/fulltext/2012/10000/Does_Atomoxetine_Improve_Executive_Function,.11.aspx |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180828 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 115856110 |a Banaschewski, Tobias |m 115856110:Banaschewski, Tobias |d 60000 |e 60000PB115856110 |k 0/60000/ |p 8 |y j | ||
| 998 | |g 1032941170 |a Dittmann, Ralf |m 1032941170:Dittmann, Ralf |d 60000 |e 60000PD1032941170 |k 0/60000/ |p 7 | ||
| 998 | |g 112354939 |a Wehmeier, Peter M. |m 112354939:Wehmeier, Peter M. |d 60000 |e 60000PW112354939 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1580475698 |e 3024085696 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1580475698","relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"zdb":["2057059-4"],"eki":["33428998X"],"issn":["1533-712X"]},"disp":"Does atomoxetine improve executive function, inhibitory control, and hyperactivity? results from a placebo-controlled trial using quantitative measurement technologyJournal of clinical psychopharmacology","recId":"33428998X","part":{"volume":"32","issue":"5","text":"32(2012), 5, Seite 653-660","extent":"8","year":"2012","pages":"653-660"},"note":["Gesehen am 21.06.2019"],"title":[{"title":"Journal of clinical psychopharmacology","title_sort":"Journal of clinical psychopharmacology"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"pubHistory":["1.1981 -"],"origin":[{"dateIssuedDisp":"1981-","publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedKey":"1981","publisherPlace":"Hagerstown, Md. ; [Erscheinungsort nicht ermittelbar]"}]}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Wehmeier, Peter M.","family":"Wehmeier","given":"Peter M."},{"family":"Dittmann","given":"Ralf","display":"Dittmann, Ralf","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Banaschewski, Tobias","family":"Banaschewski","given":"Tobias"}],"name":{"displayForm":["Peter M. Wehmeier, MD, Alexander Schacht, PhD, Fredrik Ulberstad, MSc, Martin Lehmann, PhD, Christian Schneider-Fresenius, PhD, Gerd Lehmkuhl, MD, Ralf W. Dittmann, MD, PhD, and Tobias Banaschewski, MD, PhD"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"2012"}],"language":["eng"],"title":[{"subtitle":"results from a placebo-controlled trial using quantitative measurement technology","title":"Does atomoxetine improve executive function, inhibitory control, and hyperactivity?","title_sort":"Does atomoxetine improve executive function, inhibitory control, and hyperactivity?"}],"id":{"doi":["10.1097/JCP.0b013e318267c304"],"eki":["1580475698"]},"physDesc":[{"extent":"8 S."}],"note":["Gesehen am 28.08.2018"]} | ||
| SRT | |a WEHMEIERPEDOESATOMOX2012 | ||